NMSCs	nonmelanoma skin cancers
SCC	squamous cell carcinoma
UVR	ultraviolet radiation
BCC	basal cell carcinoma
FDA	Food and Drug Administration
CSCC	cutaneous squamous cell carcinoma
PUVA	PSORALEN (P) and ultraviolet light UVA
AK	actinic keratosis
BRAF	B type rapidly accelerated fibrosarcoma kinase
JAK	Janus kinase
PDE-5	phosphodiesterase type 5
OTRs	organ transplant recipients
TERT	telomerase reverse transcriptase
MAPK	mitogen-activated protein kinase
ROS	reactive oxygen species
FOXM1	forkhead box M1
COX2	cyclooxygenase 2
MMPs	matrix metalloproteinases
HPV	human papillomavirus
CDKN2A	cyclin-dependent kinase inhibitor 2A
FAT1	FAT atypical cadherin 1
CPDs	cyclobutane pyrimidine dimers
pRB	retinoblastoma phosphorylation
HNSCC	head and neck SCC
OSCC	oral SCC
5-FU	5-fluorouracil
EGFRis	epidermal growth factor receptor inhibitors
CTLA-4	cytotoxic T-lymphocyte-associated antigen 4
PD-1	programmed cell death 1
PD-L1	programmed cell death-ligand 1
TME	tumor microenvironment
TAMs	tumor-associated macrophages
TMB	Tumor mutational burden
NGS	Next-generation sequencing
TILs	tumor-infiltrating lymphocytes
FGF	fibroblast growth factor
EGF	epidermal growth factor
TGF-β	Transforming growth factor β
VEGF	vascular endothelial growth factor
CXCLs	C-X-C motif chemokine ligands
IFN-γ	interferon-gamma
ADAR1	adenosine deaminase acting on RNA 1
YAP	yes-associated protein
irAEs	immune-related adverse events